Biologics
-
Biologics
Orthobiologics Market to Top $10.3 Billion by 2030
Increasing inorganic strategies such as product launches are expected to drive growth.Michael Barbella, Managing Editor 06.07.23
-
Biologics
Biocomposites Acquires Artoss, Maker of NanoBone Bone Graft Substitute
NanoBone technology complements Biocomposites' absorbable bone regeneration products.Sam Brusco, Associate Editor 06.06.23
-
Biologics
TendoNova Inks Partnership With AcCELLerated Biologics
TendoNova's Ocelot System performs mechanical fragmentation or debridement of a targeted tendon area.Michael Barbella, Managing Editor 05.25.23
-
Biologics | Extremities
Paragon 28 Releases Supramalleolar Osteotomy System
The system includes six plates for anterior or medial approaches as well as multiple spanning distances to accommodate varying correction.Sam Brusco, Associate Editor 05.23.23
-
Biologics
Induce Biologics Launches NMP Cancellous Strips
The product features an optimal strip design that provides ideal handling characteristics for fluid retention and expansion.Michael Barbella, Managing Editor 05.17.23
-
Biologics
Bioventus Sheds Wound Biz for $85 Million
LifeNet Health acquired the wound business—including skin substitutes TheraSkin and TheraGenesis.Sam Brusco, Associate Editor 05.10.23
-
Biologics
OssDsign Marks 1,000-Patient Milestone for its Nanosynthetic Bone Graft
Company launched OssDsign Catalyst in August 2021.Michael Barbella, Managing Editor 05.09.23
-
Biologics
Positive Results Achieved With Novadip Biosciences' Tissue Engineered Product
Results show NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing.Michael Barbella, Managing Editor 04.13.23
-
Biologics
Abyrx Earns Further FDA Nods for MONTAGE Settable, Resorbable Bone Putty
MONTAGE granted additional indications as bone void filler and cranial bone cement.Sam Brusco, Associate Editor 04.05.23
-
Biologics
Industry Innovation: A Look at Regenerative Medicine in Orthopedics
Innovation is supporting the shift to regenerative medicine as treatment for a variety of orthopedic trauma cases and bone voids.Online Exclusives Daniel Ammon, Vice President, R&D, Regenity Biosciences 04.05.23
-
Biologics
Report: No Complications With OssDsign Catalyst Graft
Company has sold more than 500 Catalyst units since the product's launch in August 2021.Michael Barbella, Managing Editor 03.30.23
-
Biologics
A More Natural Future Using Biologics?
Will all of orthopedics embrace technologies that promote a more natural healing protocol?Sean Fenske, Editor-in-Chief 03.10.23
-
3-D Printing/Additive Mfg. | Biologics
Evonik & BellaSeno Partner to Commercialize 3D-Printed Scaffolds for Bone Regeneration
The bone scaffolds are made with Evonik’s Resomer polymers and are used for large and complex bone defects.Charles Sternberg, Associate Editor 03.06.23
-
Biologics
ChitogenX Secures $3.5M Grant to Advance ORTHO-R Development
The grant comes from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec.Sam Brusco, Associate Editor 02.17.23
-
Biologics
Revolutionizing Orthopedics: The Transformative Potential of Regenerative Medicine
Look to the revolution in biologic delivery as a real option for improving treatment outcomes.Dr. Luis Alvarez, CEO and Founder, Theradaptive 02.17.23
-
Biologics
Steady Growth Forecast for Global Orthobiologics Market
Increasing prevalence of bone diseases is expected to fuel the sector's growth.Michael Barbella, Managing Editor 02.06.23
-
Biologics | Large Joint
Orthogen's IDE Trial for Knee OA Gets FDA Nod
Orthogen to launch pivotal trial of novel therapy for knee osteoarthritis.Sam Brusco, Associate Editor 01.18.23
-
Biologics | Large Joint
Lipogems Begins ARISE IDE Study for Knee OA
Will compare its MicroFat autologous, intra-articular injection versus corticosteroid injection to treat knee osteoarthritis (OA).Sam Brusco, Associate Editor 01.16.23
-
Biologics
Researchers Develop Hydrogel Injections to Treat Antibiotic-Resistant Infections
Can suppress infections and encourage healing around prosthetics without the problems caused by antibiotics and tissue grafting.Charles Sternberg, Associate Editor 01.10.23
-
Biologics | Spine/Neurology
Paul Mraz Appointed President and CEO of FzioMed
Most recently, Mraz was president and CEO of ApiFix Ltd.Michael Barbella, Managing Editor 01.09.23
